Compare CRDL & GMGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDL | GMGI |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 115.8M |
| IPO Year | N/A | N/A |
| Metric | CRDL | GMGI |
|---|---|---|
| Price | $1.05 | $0.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9.00 | $4.00 |
| AVG Volume (30 Days) | ★ 328.2K | 223.0K |
| Earning Date | 11-13-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $179,142,103.00 |
| Revenue This Year | N/A | $25.59 |
| Revenue Next Year | N/A | $14.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 37.24 |
| 52 Week Low | $0.77 | $0.58 |
| 52 Week High | $1.59 | $2.50 |
| Indicator | CRDL | GMGI |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 34.72 |
| Support Level | $0.94 | $0.65 |
| Resistance Level | $1.03 | $0.74 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 85.71 | 22.58 |
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Golden Matrix Group Inc is an established gaming technology company. The company develops and owns online gaming IP and builds configurable and scalable white-label social gaming platforms for its international customers. The company operates in three reportable segments; MeridianBet Group, GMAG, RKings & CFAC. The MeridianBet Group segment earns majority revenue. The company operates in UK, Europe, Asia Pacific, Central and South America, Australia and Africa. It offers configurable and scalable iGaming platforms and operate some of the industry's iconic brands, including MexPlay, GM-AG, and others.